NAMSNewAmsterdam Pharma Company N.V.
Is it safe?
Caution warranted: heavy debt (CCC) and big price swings.
Insiders were net sellers (-$7.6M, 90 days to Oct 8, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -66% · now 48% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can NAMS take a bad year?
The deepest fall in NAMS's price history on file is −66%; it is 48% below its high today.
Worst drawdown on file · −48% today
- Cash runway
- 4.4 years
Cash runway · burning $36M a quarter at the current rate
- Annualised volatility
- 64%
Annualised volatility · three times the market's own swing
Details›
- Cash and short-term investments
- $634M
- EBITDA, trailing twelve months
- −$244M
- Operating profit, trailing twelve months
- −$244M
- Annualised volatilitytwo years of daily moves
- 64%
- Worst drawdown on file
- −66%
- Below its 52-week high
- 48%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.